DAX

DGAP-News: BB BIOTECH AG: 2021 was a difficult year for biotech equity markets - increased dividend of CHF 3.85 proposed

Retrieved on: 
Venerdì, Gennaio 21, 2022
Net asset value, Vaccination, Technology, Patient, Vertex, Annual report, Vaccine, Biotechnology, Clinical trial, Bipolar disorder, Swings, RNA, AGM, COVID-19, Board of directors, Severe acute respiratory syndrome coronavirus 2, Blas, Policy, EUA, CEO, NBI, Nasdaq Composite, Industry, BB Biotech, Government, Annual, Executive, Beta thalassemia, Destiny, CRISPR Therapeutics, Therapy, Prognosis, Macrogen, Gene editing, GMG, Environment, SPI, NDAS, Director, NAV, Dow Jones, Blood, FDA, CRISPR, Conditional sentence, Omicron, Annual general meeting, Board, Investment, Fine chemical, Pharmaceutical industry, Bank, Alnylam Pharmaceuticals, Ionis, EUR, CHF, Neurocrine, USD

Media release as at January 21, 2022

Key Points: 
  • Media release as at January 21, 2022
    Portfolio of BB Biotech AG as at December 31, 2021
    The year 2021 was a volatile market environment for all involved in biotechnology investing, including BB Biotech.
  • BB Biotech carefully adjusted the portfolio in the last three months of 2021.
  • The net loss for BB Biotech in 2021 was CHF 405 mn.
  • The highly specialized investment team at BB Biotech believes that the growth case for biotechnology and valuations for portfolio companies are both compelling.

Daxbot Announces First Funding Round

Retrieved on: 
Venerdì, Settembre 17, 2021
CEO, City, Computer data storage

PHILOMATH, Ore., Sept. 17, 2021 /PRNewswire/ -- Today, Daxbot, Inc. announced the launch of their Regulation Crowdfunding raise.

Key Points: 
  • PHILOMATH, Ore., Sept. 17, 2021 /PRNewswire/ -- Today, Daxbot, Inc. announced the launch of their Regulation Crowdfunding raise.
  • Daxbot has several robot deployments scheduled this year in different cities across the United States.
  • The goal of the funding round is to increase the number of robots and be able to have delivery robots in 10 key cities across the United States in 2022.
  • To learn more about the Daxbot funding round, please visit: https://www.startengine.com/daxbot
    Daxbot's mission is to put robots in the service of humanity.

DGAP-News: Solid second quarter for the biotech industry - BB Biotech raised its allocation to promising small and mid caps

Retrieved on: 
Venerdì, Luglio 23, 2021
BB Biotech

BB Biotech shares returned 5.8% in CHF and 6.1% in EUR in the second quarter of 2021.

Key Points: 
  • BB Biotech shares returned 5.8% in CHF and 6.1% in EUR in the second quarter of 2021.
  • Major regulatory decisions for several companies in BB Biotech's portfolio are also expected in the second half of the year.
  • BB Biotech's share price was 5.8% in CHF and 6.1% in EUR during the second quarter 2021.
  • The quarterly report of BB Biotech AG as at June 30, 2021 can be downloaded at report.bbbiotech.ch/Q221 or www.bbbiotech.com

DGAP-News: BB BIOTECH AG: Successful vaccination campaigns point the way out of the corona crisis - sector re-valuation used for portfolio investments

Retrieved on: 
Venerdì, Aprile 23, 2021

Its stock ended the quarter with a positive total return of 15.4% in CHF and 14.3% in EUR.

Key Points: 
  • Its stock ended the quarter with a positive total return of 15.4% in CHF and 14.3% in EUR.
  • Countries such as Israel, the US and the UK that secured early access to vaccines have experienced sharp drops in infection and hospitalization rates.
  • Although most other countries are making slower progress with their vaccination campaigns, they are likely to eventually show similar developments.
  • This should have a variety of positive effects on companies in the biotech sector.

INTERSECT BY LEXUS-NYC To Welcome Three Michelin Star Restaurant, Manresa, As Next Restaurant-In-Residence And Launch New Outdoor Dining Area

Retrieved on: 
Mercoledì, Aprile 14, 2021
Lexus, Gastronomy, Japanese culture, Automotive industry

"We look forward to flexing our creativity and presenting tasting and la carte menus reflective of our Manresa fine dining experience at INTERSECT BY LEXUS.

Key Points: 
  • "We look forward to flexing our creativity and presenting tasting and la carte menus reflective of our Manresa fine dining experience at INTERSECT BY LEXUS.
  • The design concept translates Lexus\' ethosinspired design, relentless innovation, and exceptional experiencesinto a flexible, modular sidewalk seating area featuring a streamlined L-framed dining pavilion.
  • Opened in New York City on November 15, 2018, guests are able to engage with Lexus through food and culture.
  • A destination within a destination, INTERSECT offers a Restaurants-in-Residence program, allowing New Yorkers and world travelers to consistently embark upon a new gastronomic adventure.\n'

DGAP-News: BB BIOTECH AG: Vaccines leading the way out of the pandemic - increased dividend of CHF 3.60 proposed

Retrieved on: 
Venerdì, Gennaio 22, 2021
RNA, BB Biotech, RNA vaccine, Medicine, Articles, Health sciences

The biotech sector made significant strides, leading the effort against the SARS-CoV-2 virus pandemic through approved mRNA vaccines and therapeutic antibodies.

Key Points: 
  • The biotech sector made significant strides, leading the effort against the SARS-CoV-2 virus pandemic through approved mRNA vaccines and therapeutic antibodies.
  • BB Biotech exited four holdings and added three new holdings in the last three months of 2020.
  • The net gain for BB Biotech in 2020 was CHF 691 mn.
  • Weakening of the USD versus the CHF and EUR throughout the year created additional headwind for CHF and Euro-denominated performance.